JP2024522389A5 - - Google Patents
Info
- Publication number
- JP2024522389A5 JP2024522389A5 JP2023566660A JP2023566660A JP2024522389A5 JP 2024522389 A5 JP2024522389 A5 JP 2024522389A5 JP 2023566660 A JP2023566660 A JP 2023566660A JP 2023566660 A JP2023566660 A JP 2023566660A JP 2024522389 A5 JP2024522389 A5 JP 2024522389A5
- Authority
- JP
- Japan
- Prior art keywords
- atoms
- linear
- alkoxy
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110475315 | 2021-04-29 | ||
| CN202110475315.1 | 2021-04-29 | ||
| PCT/CN2022/089726 WO2022228495A1 (zh) | 2021-04-29 | 2022-04-28 | 抗体偶联药物的制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522389A JP2024522389A (ja) | 2024-06-19 |
| JP2024522389A5 true JP2024522389A5 (enExample) | 2025-04-16 |
Family
ID=83846703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566659A Pending JP2024522388A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566659A Pending JP2024522388A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20240245795A1 (enExample) |
| EP (3) | EP4331613A1 (enExample) |
| JP (3) | JP2024522388A (enExample) |
| KR (2) | KR20240006028A (enExample) |
| CN (3) | CN117241834A (enExample) |
| AU (1) | AU2022263700A1 (enExample) |
| CA (3) | CA3173511A1 (enExample) |
| IL (1) | IL308025A (enExample) |
| TW (3) | TW202308700A (enExample) |
| WO (3) | WO2022228494A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308700A (zh) * | 2021-04-29 | 2023-03-01 | 大陸商上海匯連生物醫藥有限公司 | 抗體偶聯藥物的製備方法及應用 |
| WO2024083162A1 (en) | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024149345A1 (en) * | 2023-01-11 | 2024-07-18 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
| WO2024193692A1 (zh) * | 2023-03-22 | 2024-09-26 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| WO2024212922A1 (zh) * | 2023-04-11 | 2024-10-17 | 映恩生物制药（苏州）有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| WO2024230678A1 (zh) * | 2023-05-11 | 2024-11-14 | 映恩生物科技(上海)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| AU2024274983A1 (en) * | 2023-05-19 | 2025-11-20 | Solve Therapeutics, Inc. | Drug-linkers and drug conjugates |
| WO2024250984A1 (zh) * | 2023-06-07 | 2024-12-12 | 上海维申医药有限公司 | 一种抗体药物偶联物，及其药物组合物、制备和用途 |
| EP4737483A1 (en) * | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| AU2024288808A1 (en) | 2023-07-07 | 2026-01-22 | Shanghai Escugen Biotechnology Co., Ltd. | Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof |
| AU2024319420A1 (en) * | 2023-08-04 | 2026-03-19 | Shanghai Huao Co., Ltd. | Multidrug linker and antibody-drug conjugate |
| WO2025064733A1 (en) * | 2023-09-22 | 2025-03-27 | Obi Pharma, Inc. | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| TW202525860A (zh) * | 2023-10-23 | 2025-07-01 | 大陸商上海齊魯製藥研究中心有限公司 | 喜樹鹼類藥物耦合物及其製備方法和應用 |
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025149019A1 (en) * | 2024-01-12 | 2025-07-17 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025222052A2 (en) * | 2024-04-18 | 2025-10-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2025261478A1 (en) * | 2024-06-21 | 2025-12-26 | Biotheus Inc. | Antibody drug conjugates and applications thereof |
| US20260048137A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
| WO2026037394A1 (zh) * | 2024-08-16 | 2026-02-19 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物及其用途 |
| WO2026046186A1 (en) * | 2024-08-27 | 2026-03-05 | Suzhou Bioreinno Biotechnology Limited Company | Linkers, linker conjugates and conjugate compounds thereof |
| WO2026067624A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海森辉医药有限公司 | 一种包含亲水基团的配体-药物偶联物及其在医药上的应用 |
| CN119143876B (zh) * | 2024-10-09 | 2025-09-16 | 武汉海沙百得生物技术有限公司 | 一种抗cd27l的全人源抗体或抗体片段及其应用 |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
| CN120484249B (zh) * | 2025-04-29 | 2026-03-10 | 中山大学 | 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| WO2003041660A2 (en) * | 2001-11-14 | 2003-05-22 | Rutgers, The State University | Solubilized topoisomerase poisons |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US9089614B2 (en) * | 2012-12-21 | 2015-07-28 | Bioalliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
| MX368259B (es) | 2013-04-16 | 2019-09-25 | Genentech Inc | Variantes de pertuzumab y su evaluacion. |
| CN105722851A (zh) * | 2013-04-28 | 2016-06-29 | 秦刚 | 一种新型的连接子及其制备方法和用途 |
| AU2014371934B2 (en) * | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| JP6666264B2 (ja) * | 2014-04-29 | 2020-03-13 | ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． | 新規安定型抗体薬物複合体の作製およびその応用 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP7381478B2 (ja) * | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| CA3085001C (en) | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| CN113853219B (zh) * | 2019-05-20 | 2025-01-07 | 诺华股份有限公司 | 具有包含亲水性基团的接头的抗体药物缀合物 |
| TW202308700A (zh) * | 2021-04-29 | 2023-03-01 | 大陸商上海匯連生物醫藥有限公司 | 抗體偶聯藥物的製備方法及應用 |
-
2022
- 2022-04-28 TW TW111116236A patent/TW202308700A/zh unknown
- 2022-04-28 JP JP2023566659A patent/JP2024522388A/ja active Pending
- 2022-04-28 EP EP22794965.8A patent/EP4331613A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089725 patent/WO2022228494A1/zh not_active Ceased
- 2022-04-28 AU AU2022263700A patent/AU2022263700A1/en active Pending
- 2022-04-28 CN CN202280030774.1A patent/CN117241834A/zh active Pending
- 2022-04-28 TW TW111116233A patent/TW202309045A/zh unknown
- 2022-04-28 CA CA3173511A patent/CA3173511A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089724 patent/WO2022228493A1/zh not_active Ceased
- 2022-04-28 TW TW111116237A patent/TW202308701A/zh unknown
- 2022-04-28 CA CA3173902A patent/CA3173902A1/en active Pending
- 2022-04-28 KR KR1020237041141A patent/KR20240006028A/ko active Pending
- 2022-04-28 EP EP22794964.1A patent/EP4331612A1/en active Pending
- 2022-04-28 JP JP2023566660A patent/JP2024522389A/ja active Pending
- 2022-04-28 CA CA3173758A patent/CA3173758A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089726 patent/WO2022228495A1/zh not_active Ceased
- 2022-04-28 IL IL308025A patent/IL308025A/en unknown
- 2022-04-28 US US18/557,445 patent/US20240245795A1/en active Pending
- 2022-04-28 JP JP2023566547A patent/JP2024522312A/ja active Pending
- 2022-04-28 CN CN202280030770.3A patent/CN117241833A/zh active Pending
- 2022-04-28 US US18/557,448 patent/US20240238440A1/en active Pending
- 2022-04-28 US US18/557,454 patent/US20240245799A1/en active Pending
- 2022-04-28 KR KR1020237041142A patent/KR20240006029A/ko active Pending
- 2022-04-28 EP EP22794963.3A patent/EP4331611A1/en active Pending
- 2022-04-28 CN CN202280030781.1A patent/CN117337195A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522389A5 (enExample) | ||
| JP2024522388A5 (enExample) | ||
| JP2024522312A5 (enExample) | ||
| Elgersma et al. | Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody–drug conjugate SYD985 | |
| ES2966473T3 (es) | Derivados de camptotecina | |
| JP5926759B2 (ja) | 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 | |
| JP2012522512A5 (enExample) | ||
| JP2022530524A5 (enExample) | ||
| JP2020526584A5 (enExample) | ||
| RU2017131902A (ru) | Цитотоксические производные бензодиазепина | |
| JP2012522513A5 (enExample) | ||
| ME00969B (me) | Citotoksična sredstva koja uključuju nove derivate tomajmicina i njihova upotreba u terapiji | |
| JP2019502650A5 (ja) | 抗ＥｒｂＢ２抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用 | |
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
| AR063872A1 (es) | Derivados de acetileno como inhibidores de estearoil coa desaturasa | |
| JP2017514905A5 (enExample) | ||
| JP2012516896A5 (enExample) | ||
| PT1242401E (pt) | Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico | |
| MXPA05001282A (es) | Conjugados efectores nuevos, procedimiento para su produccion y su uso farmaceutico. | |
| JP2024542021A5 (enExample) | ||
| JP2023514520A (ja) | ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体－薬物複合体 | |
| RU2023112017A (ru) | Дейтерированное производное камптотецина и включающий его конъюгат антитело-лекарственное средство | |
| RU2023130984A (ru) | Способ получения и применение конъюгата антитело-лекарственное средство | |
| RU2025129383A (ru) | Конъюгат антитело-лекарственное средство | |
| RU2025125775A (ru) | Конъюгат антитело-лекарство, способ его получения и применение |